Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $67.32 USD
Change Today +0.61 / 0.91%
Volume 1.8M
ISIS On Other Exchanges
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Isis Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of USD 62,583,000 compared to USD 28,161,000 a year ago. Loss from operations was USD 9,330,000 compared to USD 29,667,000 a year ago. Loss before income tax benefit was USD 17,506,000 compared to USD 33,556,000 a year ago. Net loss was USD 16,717,000 or USD 0.14 per basic and diluted share compared to USD 31,280,000 or USD 0.27 per basic and diluted share a year ago. Pro forma income from operations was USD 3,975,000 compared to pro forma loss from operations of USD 22,598,000 a year ago. Pro forma net loss was USD 3,412,000 compared to USD 24,211,000 a year ago. Net loss was decreased primarily due to an increase in revenue from milestone payments. With continuing opportunities to earn additional milestone payments from its partners as he company progress through the year 2015, puts on track to exceed its guidance of a pro forma net operating loss in the mid USD 50 million range and more than USD 630 million in cash.

Isis Pharmaceuticals, Inc. Enters into Exclusive License Agreement with Bayer Healthcare to Develop and Commercialize ISIS-FXIRx for the Prevention of Thrombosis

Isis Pharmaceuticals, Inc. entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of thrombosis. Under the terms of the agreement, the company is eligible to receive up to $155 million in near-term payments, including an immediate $100 million up-front payment and a $55 million payment upon advancement of the program following a Phase 2 study in patients with compromised kidney function. Isis is also eligible to receive milestone payments as the drug advances toward the market. In addition, Isis is eligible to receive tiered royalties in the low to high 20% range on gross margins of ISIS-FXIRx. After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx. As part of the clinical development program, Bayer plans to evaluate the therapeutic profile of ISIS-FXIRx in patients for whom currently available anticoagulants may not be used, such as in patients with a high risk of bleeding due to multiple co-morbidities. This transaction is subject to clearances under the Hart-Scott Rodino Antitrust Improvements Act.

Isis Pharmaceuticals Reports Positive Data from ISIS-TTR Rx in Patients With TTR Amyloidosis

Isis Pharmaceuticals, Inc. announced positive data from an ongoing open-label extension (OLE) study of ISIS-TTR Rx in patients with familial amyloid polyneuropathy (FAP). FAP patients completing the ongoing Phase 3 study are eligible to enroll in this OLE study in which all patients receive ISIS-TTRRx. An analysis conducted on the first group of patients to reach three months of treatment in the OLE study showed a reduction in transthyretin (TTR) protein levels up to 92% with a median reduction of 78% compared to patients' baseline TTR levels at entry into the Phase 3 study. Patients continue to be enrolled as they complete dosing in the Phase 3 study.

Isis Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 05, 2015

Isis Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 05, 2015

Isis Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 09:20 AM

Isis Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 09:20 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Elizabeth L. Hougen, Chief Financial Officer and Senior Vice President of Finance.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $67.32 USD +0.61

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $41.20 USD +1.01
Acorda Therapeutics Inc $30.48 USD 0.00
Aegerion Pharmaceuticals Inc $19.48 USD -0.20
Depomed Inc $20.86 USD +0.16
Regulus Therapeutics Inc $14.12 USD +0.54
View Industry Companies

Industry Analysis


Industry Average

Valuation ISIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.9x
Price/Book 28.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at